Skip to content

Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm

Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02814201
Acronym
ERAMPPCI
Enrollment
55
Registered
2016-06-27
Start date
2011-07-31
Completion date
2016-11-30
Last updated
2016-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease, Huntington Disease

Keywords

Motor slowing, Computerized mental chronometry paradigm

Brief summary

Action slowing has been demonstrated in many diseases. Parkinson's disease (PD) and Huntington's disease (HD) are two neurodegenerative diseases affecting the basal ganglia, particularly the medial globus pallidus, and the clinical expression of these two diseases is characterized by a combination of motor and cognitive disorders, but with two opposing patterns of dysfunction. Action slowing has been demonstrated in both of these diseases and has been extensively studied in Parkinson's disease, suggesting a perceptive-cognitive origin. Far fewer studies have been conducted in Huntington's disease. However, all of these studies were performed with different methodologies in small cohorts and the value of the proposed study is to use a validated and standardized computerized mental chronometry paradigm, providing a better understanding of the mechanisms of action slowing in these two diseases and to more clearly define a disease-specific profile.

Interventions

BEHAVIORALSRT

simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Agreeing to participate in the study * French mother tongue * MMSE \> 20/30 * Specific to the MP and MH: * Parkinson's disease: * defined by the criteria of the UKPDSBB * stage 1 , 2 or 3 Hoehn and Yahr (ON) * age of onset of the disease known * brain MRI performed during follow-up * Huntington disease : * genetically defined (CAG \> 35) * weaning neuroleptic ( Tercian® and Solian® : 2 days; Haldol® : 5 days ; Tiapridal® and Xenazine : 1 day ; Zyprexa® : 4 days) * Early stage : Fahn and Shoulson I and II is a CFT score between 7 and 13

Exclusion criteria

* Illiteracy, writing or reading difficulties * Visual perceptual auditory deficit or preventing reading, drawing, writing or understanding instructions * Visual hallucinations * Significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic alcoholism weaned or not) * Current or previous neurological diseases other than MH or MP: ischemic cerebral vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes), epilepsy requiring treatment. * Psychiatric disorders depression unless treated (stable treatment for 1 month) * Psychotropic treatment (except anxiolytic, antidepressant steady since 1 month) * Inability to achieve an autonomous operation without technical assistance over a distance of 20 meters. * Inability to stand without technical assistance for 30 seconds.

Design outcomes

Primary

MeasureTime frameDescription
SRTDay 0simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026